Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Depression is common in people with Alzheimer's disease (AD) affecting overall outcomes and decreasing quality of life. Although depression in AD is primarily treated with antidepressants, there are few randomized controlled trials (RCTs) assessing efficacy and results have been conflicting. OBJECTIVES: To systematically review evidence on efficacy of antidepressant treatments for depression in AD. METHODS: Systematic review and meta-analysis of double blind RCTs comparing antidepressants versus placebo for depression in AD. We searched MEDLINE, CINAHL, EMBASE, PsycINFO, the Cochrane Controlled Trials Register and on line national and international registers. Primary outcomes were treatment response and depressive symptoms. Secondary outcomes were cognition, acceptability, and tolerability. Risk of bias was also assessed. RESULTS: Seven studies met inclusion criteria. Three compared sertraline with placebo; one compared both sertraline and mirtazapine to placebo; imipramine, fluoxetine, and clomipramine were evaluated in one study each. In terms of response to treatment (6 studies, 297 patients treated with antidepressants and 223 with placebo), no statistically significant difference between antidepressants and placebo was found (odds ratio (OR) 1.95, 95% CI 0.97-3.92). We found no significant drug-placebo difference for depressive symptoms (5 studies, 311 patients, SMD -0.13; 95% CI -0.49 to 0.24). Overall quality of the evidence was moderate because of methodological limitations in studies and the small number of trials. CONCLUSION: Despite the importance of depression in people with AD, few RCTs are available on efficacy of antidepressants, limiting clear conclusions of their potential role. There is a need for further high quality RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Limited information is available on the efficacy of antidepressants amongst older people with cognitive impairment and dementia (Boyce 2012;Nelson 2011;Orgeta 2017), which is problematic given the high prevalence of these conditions in the LTC population.”
From Psychological therapies for depression in older adults residing in long-term care settings (2024) · cites this paper as Orgeta 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuropsychiatric symptoms are common and often clustered in people with dementia.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients suffering from AD are more prone to comorbid depression [40, 41]”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These symptoms might precede dementia and are associated with tau and amyloid neuropathology.210”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [210]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“We used the GRADE approach [41] to summarize overall quality of evidence.”
MethodCognitive Stimulation in Patients with Dementia: Randomized Controlled Trial
Mapelli, D., Di Rosa, E., Nocita, R., & Sava, D. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353457 · Cited by 3,453
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247 · cited 1×
“cognitive impairment is the hallmark of the illness, neuropsychiatric symptoms affect almost all patients and are persistent [3, 4].”
BackgroundPredictors of nursing home admission for persons with dementia
Gaugler, J. E., Yu, F., Krichbaum, K., & Wyman, J. F. (2009) · Medical Care · doi:10.1097/mlr.0b013e31818457ce · Cited by 617
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398 · cited 2×
“Three studies compared sertraline with placebo [19, 21, 46], one RCT compared both sertraline and mirtazapine to placebo [47]; imipramine [20], fluoxetine [22], and clomipramine [18] were examined in one study each.”
BackgroundResult
Research works printed but not linked: 1
- Knapp M, Comas-Herrera A, Wittenberg R, Hu B, King D, Rehill A, Adelaja B (2014) Scenarios of dementia care: What are the impacts on cost and quality of life? PSSRU Discussion Paper, 2878, Personal Social Services Research Unit, London, UK.
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Self-citationRetractedBrain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Antidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
Astrocytes and the TGF-β1 Pathway in the Healthy and Diseased Brain: a Double-Edged Sword
Diniz, L. P., Matias, I., Siqueira, M., Stipursky, J., & Gomes, F. C. A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1396-y · Cited by 159
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 177
Pless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., & Wang, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1263771 · Cited by 131
Serotonergic system, cognition, and BPSD in Alzheimer’s disease
Chakraborty, S., Lennon, J. C., Malkaram, S. A., Zeng, Y., Fisher, D. W., & Dong, H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.050 · Cited by 133
Depression and Dementia in Older Adults: A Neuropsychological Review
Tetsuka, S. (2021) · Aging and Disease · doi:10.14336/ad.2021.0526 · Cited by 128
Herrera-Perez, D., Haslam, A., Crain, T., Gill, J., Livingston, C., Kaestner, V., Hayes, M., Morgan, D., Cifu, A. S., & Prasad, V. (2019) · eLife · doi:10.7554/elife.45183 · Cited by 116
Diagnosing and Treating Depression in Patients with Alzheimer’s Disease
Burke, A. D., Goldfarb, D., Bollam, P., & Khokher, S. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00148-5 · Cited by 115
Psychological treatments for depression and anxiety in dementia and mild cognitive impairment
Orgeta, V., Leung, P., del-Pino-Casado, R., Qazi, A., Orrell, M., Spector, A. E., & Methley, A. M. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009125.pub3 · Cited by 103
Self-citationGarcía-García, M. L., Tovilla‐Zárate, C. A., Villar-Soto, M., Juárez‐Rojop, I. E., González‐Castro, T. B., Mendoza, A. D. G., Ramos-Méndez, M. Á., López‐Narváez, M. L., Saucedo-Osti, A. S., Ruiz-Quiñones, J. A., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114317 · Cited by 90
Agüera-Ortíz, L., García-Ramos, R., Pérez, F. J. G., López‐Álvarez, J., Rodríguez, J. M. M., Rodríguez, F. J. O., Pueyo, J. O., Valero, C. P., & Porta-Etessam, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.638651 · Cited by 95
Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer’s Disease
Wolinsky, D., Drake, K., & Bostwick, J. R. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0978-8 · Cited by 79
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Harrison, S. L., Cations, M., Jessop, T., Hilmer, S. N., Sawan, M. J., & Brodaty, H. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0623-6 · Cited by 66
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Cacabelos, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093059 · Cited by 66
Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease
Heilman, K. M., & Nadeau, S. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01172-w · Cited by 64
Fidélis, E. M., Savall, A. S. P., Abreu, E. D. L., de Carvalho, F. B., Teixeira, F. E. G., Haas, S. E., Sampaio, T. B., & Pinton, S. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.032 · Cited by 63
Cumbo, E., Cumbo, S., Torregrossa, S., & Migliore, D. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.24 · Cited by 57
Zhang, S., Lu, Y., Chen, W., Shi, W. Q., Zhao, Q., Zhao, J., & Li, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s315060 · Cited by 54
He, Y., Li, H., Huang, J., Huang, S., Bai, Y., Li, Y., & Huang, W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211030181 · Cited by 61
Hsu, T., Stubbs, B., Liang, C., Chen, T., Yeh, T., Pan, C., & Chu, C. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101362 · Cited by 52
Lozupone, M., La Montagna, M., D’Urso, F., Piccininni, C., Sardone, R., Dibello, V., Giannelli, G., Solfrizzi, V., Greco, A., Daniele, A., et al. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1471136 · Cited by 50
Hussain, M., Kumar, P., Khan, S., Gordon, D. K., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.11613 · Cited by 49
Pagonabarraga, J., Álamo, C., Castellanos, M., Díaz, S., & Manzano, S. (2023) · Brain Sciences · doi:10.3390/brainsci13020318 · Cited by 53
Depression in Alzheimer’s Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?
Elsworthy, R. J., & Aldred, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180780 · Cited by 74
Nikolenko, V. N., Oganesyan, M. V., Rizaeva, N. A., Kudryashova, V. A., Nikitina, A. T., Pavliv, M. P., Анатольевна, Щ. М., Db, G., Bulygin, K. V., & Sinelnikov, M. Y. (2020) · Brain Sciences · doi:10.3390/brainsci10080502 · Cited by 51
Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies
Zhang, Y., Liang, M., Sun, C., Song, E. J., Cheng, C., Shi, T., Min, M., & Sun, Y. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02753-7 · Cited by 50
Long, Y., Li, D., Yu, S., Shi, A., Deng, J., Wen, J., Li, X., Ma, Y., Yu-lu, Z., Liu, S., et al. (2022) · Food & Function · doi:10.1039/d2fo01287a · Cited by 45
APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline
Fang, W., Xiao, N., Zeng, G., Bi, D., Dai, X., Mi, X., Ye, Q., Chen, X., & Zhang, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01631-0 · Cited by 42
Döme, P., Kunovszki, P., Takács, P., Fehér, L., Balázs, T., Dede, K., Mulhern-Haughey, S., Barbreau, S., & Rihmer, Z. (2021) · PLOS ONE · doi:10.1371/journal.pone.0245510 · Cited by 40
Pyka, P., Haberek, W., Więcek, M., Szymańska, E., Ali, W., Cios, A., Jastrzębska‐Więsek, M., Satała, G., Podlewska, S., Giacomo, S. D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02148 · Cited by 43
Moth, A. E., Hølmkjær, P., Holm, A., Rozing, M. P., & Overbeck, G. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00875-1 · Cited by 44
Treatment Options for Agitation in Dementia
Ringman, J. M., & Schneider, L. S. S. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0572-3 · Cited by 40
Bingham, K. S., Flint, A. J., & Mulsant, B. H. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1047-7 · Cited by 42
Xue, B., Xiao, A., Luo, X., & Li, R. (2021) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1887 · Cited by 40
Huang, J., Chen, B., Wang, H., Hu, S. S., Yu, X., Reilly, J., He, Z., You, Y., & Shu, X. (2022) · Cells · doi:10.3390/cells11233730 · Cited by 33
Qu, X., Zhang, L., & Wang, L. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c06238 · Cited by 36
Fonseca, C., Ettcheto, M., Bicker, J., Fernandes, M. J., Falcão, A. C., Camins, A., & Fortuna, A. C. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101998 · Cited by 32
Defrancesco, M., Marksteiner, J., Kemmler, G., Dal‐Bianco, P., Ransmayr, G. N., Benke, T., Mosbacher, J. A., Höller, Y., & Schmidt, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190662 · Cited by 29
Zhang, J., Zheng, X., & Zhao, Z. (2023) · BMC Neurology · doi:10.1186/s12883-023-03191-w · Cited by 33
Guo, Z., Liu, X., Xu, S., Hou, H., Chen, X., Zhang, Z., & Chen, W. (2018) · Neuroradiology · doi:10.1007/s00234-018-2100-7 · Cited by 30
Clement, A., Wiborg, O., & Asuni, A. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00056 · Cited by 28
Pharmacogenetics of Anxiety and Depression in Alzheimer’s Disease
Cacabelos, R., Carril, J. C., Corzo, L., Pego, R., Cacabelos, N., Alcaraz, M., Muñiz, A., Martínez-Iglesias, O. A., & Naidoo, V. (2023) · Pharmacogenomics · doi:10.2217/pgs-2022-0137 · Cited by 27
Yao, Y., Lin, D., Chen, Y., Liu, L., Wu, Y., & Zheng, X. (2023) · Inflammation Research · doi:10.1007/s00011-023-01738-8 · Cited by 28
Psychological therapies for depression in older adults residing in long-term care settings
Davison, T. E., Bhar, S., Wells, Y., Owen, P. J., You, E., Doyle, C., Bowe, S. J., & Flicker, L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013059.pub2 · Cited by 25
Kwon, K. J., Kim, H. Y., Han, S., & Shin, C. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111338 · Cited by 24
Byrns, A., Abdessalem, H. B., Cuesta, M., Bruneau, M., Belleville, S., & Frasson, C. (2020) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2020.138018 · Cited by 26
Liao, Y., Wang, Y., Tao, Q., Yang, C., Wang, J., Cheng, J., Ma, J., Wu, Z., Pan, R., & Yuan, Z. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13366 · Cited by 25
Kotagale, N. R., Deshmukh, R. A., Vinchurney, M. D., Fating, R., Umekar, M. J., & Taksande, B. G. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.04.013 · Cited by 23
Tang, C., Wang, Y., & Hong, H. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116482 · Cited by 22
Lü, W., Liu, F., Zhang, Y., He, X., Hu, Y., Xu, H., Yang, X., Li, J., & Kuang, W. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2024-301019 · Cited by 23
Hernández, D. J. Q., Rojas‐Hernández, J., Santana, Á., Suárez, C. C., Silva, M. P., Barrachina, M. T. M., Fernández, I. I., López, J. A. E., & Borkel, L. F. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220889 · Cited by 23
Zhang, M., Liu, L., Xu, Y., Wang, W.-Z., Qiu, N., Zhang, F., Zhang, F., Wang, X., Chen, W., Xu, X.-Y., et al. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01242-2 · Cited by 26
Padovani, A., Antonini, A., Barone, P., Bellelli, G., Fagiolini, A. M., Ferini‐Strambi, L., Sorbi, S., & Stocchi, F. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06891-w · Cited by 23
Use of Falls Risk Increasing Drugs in Residents at High and Low Falls Risk in Aged Care Services
Wang, K., Bell, J. S., Gilmartin‐Thomas, J., Tan, E. C. K., Cooper, T., Robson, L., & Ilomäki, J. (2019) · Journal of Applied Gerontology · doi:10.1177/0733464819888848 · Cited by 22
Current approaches to the pharmacological treatment of Alzheimer’s disease
Tan, E. C. K., Hilmer, S. N., Ptacek, S. G., & Bell, J. S. (2018) · Australian Journal of General Practice · doi:10.31128/ajgp-05-18-4586 · Cited by 25
Carotenuto, A., Fasanaro, A. M., Manzo, V., Amenta, F., & Traini, E. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200269 · Cited by 22
Sánchez-Nieto, D., Castaño-Castaño, S., Martos, R. N., Obrero‐Gaitán, E., Cortés‐Pérez, I., & Nieto-Escámez, F. A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20032727 · Cited by 22
Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants
Verkhratsky, A., Parpura, V., Scuderi, C., & Li, B. (2021) · Advances in Neurobiology · doi:10.1007/978-3-030-77375-5_13 · Cited by 19
Marcinkowska, M., Bucki, A., Śniecikowska, J., Zagórska, A., Fajkis-Zajączkowska, N., Siwek, A., Głuch‐Lutwin, M., Żmudzki, P., Jastrzębska‐Więsek, M., Partyka, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00497 · Cited by 20
Brucki, S. M. D., Aprahamian, I., Borelli, W. V., Calil, V., Ferretti‐Rebustini, R. E. D. L., Smid, J., Barbosa, B. J. A. P., Schilling, L. P., Balthazar, M. L. F., Frota, N. A. F., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s107pt · Cited by 32
Verdaguer, E. S., Stafford, J., Tuijt, R., & Orgeta, V. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.053 · Cited by 18
Self-citationCognitive Impairment, Dementia and Depression in Older Adults
Jang, Y. J., Chang, J. H., Moon, D. U., & Jeon, H. J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031198 · Cited by 18
Rocha, F. L., Cunha, U. G. D. V., PASCHOALIN, R. C., Hara, C., & Thomaz, D. P. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000334 · Cited by 16
Yang, B., Tao, B., Yin, Q., Chai, Z., Xu, L., Zhao, Q., & Jun, W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.801209 · Cited by 18
McCombie, C., Cort, E., Gould, R. L., Kiosses, D. N., Alexopoulos, G. S., Howard, R. J., & Lawrence, V. C. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.05.025 · Cited by 16
Self-citationBoussageon, R., Blanchard, C., Charuel, É., Ménini, T., Pereira, B., Naudet, F., Kassaï, B., Gueyffier, F., Cucherat, M., & Vaillant-Roussel, H. (2022) · Therapies · doi:10.1016/j.therap.2022.10.008 · Cited by 22
Pilozzi, A. R., Foster, S. L., Mischoulon, D., Fava, M., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512513 · Cited by 17
Hvidsten, L., Engedal, K., Selbæk, G., Wyller, T. B., Benth, J. Š., & Kersten, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180479 · Cited by 15
Cumbo, E., Adair, M., Åström, D. O., & Christensen, M. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1037816 · Cited by 17
Clinical Deep Phenotyping of ABCA7 Mutation Carriers
Campbell, A. S., Ho, C. C. G., Atık, M., Allen, M., Lincoln, S., Malphrus, K., Nguyen, T., Oatman, S. R., Corda, M., Conway, O., et al. (2022) · Neurology Genetics · doi:10.1212/nxg.0000000000000655 · Cited by 14
Waiker, D. K., Verma, A., Gajendra, T. A., NAMRATA, N., Roy, A., Kumar, P., Trigun, S. K., Srikrishna, S., Krishnamurthy, S., Davisson, V. J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116409 · Cited by 14
Hu, Q., Zhao, M., Teng, F., Lin, G., Jin, Z., & Xu, T. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01730-0 · Cited by 18
Callegari, E., Benth, J. Š., Selbæk, G., Grønnerød, C., & Bergh, S. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.08.034 · Cited by 15
García‐Alberca, J. M., Gris, E., de la Guía, P., & Mendoza, S. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215630 · Cited by 14
Digging into the intrinsic capacity concept: Can it be applied to Alzheimer’s disease?
López‐Ortiz, S., Caruso, G., Emanuele, E., Menéndez, H., Peñín‐Grandes, S., Guerrera, C. S., Caraci, F., Nisticò, R., Lucía, A., Santos‐Lozano, A., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102574 · Cited by 14
LAM, L. C. W., Lee, A. T. C., Cheng, S., Yip, B. H. K., Chan, W. C., Fung, A. W. T., Ma, S. L., Cheng, C. P.-W., Kong, R., Chiu, H. T. S., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.721583 · Cited by 14
Zhao, Y., Yu, Q., Hu, X., Chen, X., Jiang, Y.-P., Jin, X.-J., Li, G., Li, Z.-H., Yang, J., Cui, S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406127 · Cited by 17
Neurobiological and therapeutic landmarks of depression associated with Alzheimer’s disease dementia
Untu, I., Davidson, M., Stanciu, G. D., Rabinowitz, J., Dobrin, R., Vieru, D. S., & Tamba, B.-I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1584607 · Cited by 17
Psycho-Neuro-Endocrine-Immunology: A Role for Melatonin in This New Paradigm
Bitzer-Quintero, O. K., Ortíz, G. G., Jaramillo-Bueno, S., Ramos-González, E. J., Márquez-Rosales, M. G., Delgado-Lara, D. L. C., Torres-Sánchez, E. D., Tejeda-Martínez, A. R., & Ramírez-Jirano, L. J. (2022) · Molecules · doi:10.3390/molecules27154888 · Cited by 14
Management of Psychiatric Symptoms in Dementia
Ayhan, Y., Yoseph, S. A., & Miller, B. L. (2022) · Neurologic Clinics · doi:10.1016/j.ncl.2022.05.001 · Cited by 13
Synthesis and Biological Activity Evaluation of Benzothiazole-Isoquinoline Derivatives
Liu, W., Guan, L., Donghai, Z., Hu, Y.-M., Zhu, Y.-X., Zhu, Y.-X., Zhang, L., Jin, L., Guan, L., & Wang, S.-H. (2022) · Molecules · doi:10.3390/molecules27249062 · Cited by 13
Chu, C., Pan, W., Ren, Y., Mao, P., Yang, C., Liu, C., & Tang, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1243894 · Cited by 13
Cacabelos, R., Carril, J. C., Corzo, L., Fernández‐Novoa, L., Pego, R., Cacabelos, N., Cacabelos, P., Alcaraz, M., Tellado, I., & Naidoo, V. (2021) · Pharmaceuticals · doi:10.3390/ph14040366 · Cited by 13
Zhao, J., Jia, Y., Zhao, W., Chen, H., Zhang, X., Ngo, F. Y., Luo, D., Song, Y., Lao, L., & Rong, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/7716201 · Cited by 14
Management of Behavioral and Psychological Symptoms in Dementia
Braun, M. (2019) · Clinical handbooks in neuropsychology · doi:10.1007/978-3-319-93497-6_23 · Cited by 15
Padovani, A., Caratozzolo, S., Benussi, A., Galli, A., Rozzini, L., Cosseddu, M., Turrone, R., & Pilotto, A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.132 · Cited by 13
Kettunen, R., Taipale, H. T., Tolppanen, A., Tanskanen, A. J., Tiihonen, J., Hartikainen, S. A., & Koponen, M. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2591-5 · Cited by 13
TSPO ligand etifoxine attenuates LPS-induced cognitive dysfunction in mice
Zhang, H., Ma, L., Guo, W.-Z., Jiao, L.-B., Zhao, H., Ma, Y., & Hao, X. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.10.013 · Cited by 13
Probable Causes of Alzheimer’s Disease
Adams, J. D., Jr. (2021) · Sci · doi:10.3390/sci3010016 · Cited by 14
Zhao, Y., Qiu, C., Lin, P., Yang, M., Huang, L., Zhao, Z., Wu, X., & Zhou, D. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1460853 · Cited by 11
Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics
Teixeira, A. L., Gregg, A. P., Gentry, M. T., Gujral, S., Rapp, E., Oberlin, L. E., Ajilore, O., Weisenbach, S. L., & Patrick, R. E. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240046 · Cited by 13
Domiciliary tDCS in Geriatric Psychiatric Disorders: Opportunities and Challenges
Rangarajan, S. K., Suhas, S., Mukku, S. S. R., Sreeraj, V. S., Sivakumar, P. T., & Venkatasubramanian, G. (2021) · Indian Journal of Psychological Medicine · doi:10.1177/02537176211003666 · Cited by 12
Combination psychotropic medicine use in older adults and risk of hip fracture
(2019) · Australian Prescriber · doi:10.18773/austprescr.2019.011 · Cited by 10
Assessment and treatment of depression associated with dementia
Hughes, L. D., Murphy, F., & Findlay, D. J. (2019) · British Journal of Hospital Medicine · doi:10.12968/hmed.2019.80.3.151 · Cited by 11
Metadata
- Authors
- Orgeta, V., Tabet, N., Nilforooshan, R., & Howard, R.
- Affiliations
- Brighton and Sussex Medical School (GB)
- Corresponding author
- Orgeta, Vasiliki
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-06-05
- Volume
- 58
- Issue
- 3
- Pages
- 725-733
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5467718
- OpenAlex
- W2612913686
- Cited by
- 203
- References
- 50
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 29 · 2023: 23 · 2022: 30 · 2021: 30 · 2020: 18 · 2019: 25 · 2018: 15
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Funders
- Alzheimer's Society
- National Institute for Health and Care Research
- University College London
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, depression
- MeSH terms
- Alzheimer Disease, Antidepressive Agents, Depressive Disorder, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.